Cure8 research brief
The work suggests new molecular readouts (fecal metaproteomics and lysine crotonylation) that could help explain why some people with ulcerative colitis respond to FMT while others do not, potentially guiding future biomarker development or mechanistic studies.
Researchers studying the microbiome and host–microbe interactions, translational scientists developing FMT biomarkers, and clinicians with research interest in FMT for ulcerative colitis.
This is a research preprint (posted on bioRxiv) describing analysis of 87 fecal samples from 23 patients collected before and up to 12 weeks after FMT.
Responders showed greater complexity in fecal proteins and Kcr sites, enrichment of taxa like Prevotella and Faecalibacterium, increased microbial proteins linked to short-chain fatty acid metabolism and related pathways, and reductions in host neutrophil-related inflammatory signatures.
The authors propose Kcr as an understudied, metabolite-sensitive molecular layer connecting microbial metabolic restoration with reduced host inflammation. The study is hypothesis-generating: it nominates candidate baseline proteins and longitudinal molecular changes associated with response but does not by itself establish clinical utility of these markers.
Methods involve metaproteomics and crotonylation profiling rather than standard clinical biomarkers.
Preprint on bioRxiv; not peer-reviewed. Small cohort (23 patients) and exploratory molecular assays mean results require independent validation before changing clinical practice.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study suggests that specific gut bacteria targeted by systemic IgG are associated with UC activity and inflammation, which could eventually help identify microbial signals linked to flares or systemic inflammation.
The finding links a specific mucus-associated protein (HMGB1) to barrier defects in Crohn’s disease, which could help explain how bacteria reach and inflame tissue in active lesions and point to future biomarker or...
The study introduces a colon-targeted EGCG delivery system that reduced inflammation and improved microbial and metabolic markers in a mouse model of UC, suggesting a potential new therapeutic approach worth further...
